EUCTR2008-002735-32-NL进行中（未招募）不适用
A double blind, randomized, placebo controlled cross-over study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subjects with Female Sexual Dysfunction in combination with SSRI use. - Lybrido(s) and SSRIs@Home
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Provision of written informed consent.
- •2.Female 21 – 70 years of age with Hypoactive Sexual Desire Disorder and/or Female Sexual Arousal Disorder and/or SSRI induced sexual disfunctioning; subjects must have experienced low sexual arousal and / or low sexual desire for at least one month prior to study entry according to DSM IV criteria. The diagnosis will be made by an experienced psychologist/sexologist.
- •3.Usage of a SSRI for at least 3 months.
- •4.The SSRI must be on a stable dose for at least 6 weeks.
- •5.Healthy according to normal results of medical history, physical examination, laboratory values and vital signs, unless the investigator considers an abnormality to be clinically irrelevant.
- •6.Subjects must have a heterosexual relationship.
- •7.Subjects must have developed FSD before using SSRIs or developed FSD during the usage of a SSRI.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1Use of oral contraception containing anti-androgens (Like Diane 35 or Minerva);
- •2Use of oral contraception containing 50 µg estrogen or more;
- •3Pregnancy, or intention to become pregnant during this study (Note: a serum or urine pregnancy test will be performed in all women prior to the administration of study medications);
- •4A pelvic inflammatory disease or an untreated vaginal infection at screening;
- •5Lactating or subjects who have given birth in the previous 6 months;
- •6Previous prolapse and incontinence surgery affecting the vaginal wall;
- •7Women with other unexplained gynecological complaints, such as abnormal uterine bleeding patterns;
- •8History of endocrinological treatment or current endocrinological treatment (with the exception of the use oral contraceptives and of fertility-promoting treatment);
- •9History of neurological treatment or current neurological treatment;
- •10History of serious psychiatric treatment (e.g.,schizophrenia, psychosis) or current treatment for psychiatric disorders like obsessive compulsive disorder, and anorexia nervosa.
- •11Any underlying cardiovascular condition including unstable angina pectoris, that would preclude sexual activity;
- •12History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months;
- •13Uncontrolled atr ial fibrillation/flutter at screening (ventricular response rate > 100 bpm), or other significant abnormality observed on ECG;
- •14Systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg. For subjects with age > 60 years and without diabetic mellitus, familiar hypercholesterolemia or cardiovascular disease: Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 90 mmHg (According to the CBO-guideline hypertension (CBO.2000a)). Systolic blood pressure < 90 mmHg and/or diastolic blood pressure <50 mmHg.
- •15Subjects who are taking strong CYP3A4-inhibitors: ritonavir (HIV-proteaseremmer), ketoconazol en itraconazol
- •16Subjects who are taking less strong CYP3A4-inhibitors: claritromycine, erytromycine en saquinavir
- •17Subjects who are taking CYP3A4-inducers: carbamazepine, fenytoïne, fenobarbital, st Johns Wort, rifampicine
- •18Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;
- •19Use of medicinal herb as Ginkgo Biloba, St John's wort and nutrition containing grapefruit; avoid valerian, gotu kola, kava kava (may increase CNS depression)
- •20Subjects who are taking nitrates or nitric oxide donors;
- •21Subjects who are taking MAO inhibitors (includes classic MAO inhibitors and linezolid), Calcium channel blockers (e.g. Diltiazem and verapamil), Nefazodone, Trazodon, TCAs, tramadol, any medicine belonging to the triptans (i.e. sumatriptan).
- •22A substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study; mild or moderately alcohol drinking behavior is allowed, only 12 hours before the experimental days is alcohol drinking not allowed. Three weeks before the start of the experimental day is the taking of any recreational drug not allowed. Smoking is allowed.
- •23Use of any treatment for FSD within the 7 days before visit 1 or during the study, including oral medications or constrictive devices;
- •24Subjects who are illiterate, unwilling or unable to understand and complete the questionnaires;
- •25Any other clinically signifi
研究者
相似试验
进行中（未招募）
1 期
A double blind, randomised, placebo controlled crossover study of intra-trigonal injections of Botulinum toxin type B for treating patients with idiopathic detrusor overactivity refractory to other conservative treatments. - Neurobloc crossoverIdiopathic detrusor overactivityEUCTR2005-004716-75-GBSwansea NHS Trust20
已完成
2 期
A double-blind, randomised, placebo controlled crossover study on the effects of 100mg, three times daily, Z-338 on the symptomatic response to a nutrient challenge and gasteric nutrient distribution and emptying in subjects with and without functional dyspepsia.Functional dyspepsiaOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12605000794606Zeria Pharmaceutical Co., Ltd52
招募中
2 期
A double blind, placebo controlled, randomized crossover, pilot study of topical RM191A spray for the relief of neuropathic paiACTRN12617000206325RR MedSciences Pty Ltd22
进行中（未招募）
1 期
The influence of ivabradine on the symptoms of neuropathic pain in a healthy volunteer pain model (IIVOP)europathic PainMedDRA version: 16.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2012-005627-32-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge24
已完成
不适用
A double-blind, placebo controlled, randomized cross-over trial to evaluate the effect of milk peptides ingestion on thermoregulation and alleviate fatigue in healthy humansJPRN-UMIN000030145iigata University10